Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Myositis

Insights into juvenile myositis via engineered muscle

Nature Reviews Rheumatology volume 19, pages 543–544 (2023)Cite this article

Subjects

The pathogenesis of juvenile dermatomyositis (JDM) is complex and various evidence implicate a role for type I interferons. Could the use of a bioengineered paediatric skeletal muscle model provide insight into this disease and have potential for high throughput testing of therapeutic agents?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Papadopoulou, C., Chew, C., Wilkinson, M. G. L., McCann, L. & Wedderburn, L. R. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat. Rev. Rheumatol. 19, 343–362 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kim, H. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy. Curr. Opin. Rheumatol. 33, 371–377 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Covert, L. T. et al. Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis. Rheumatology (Oxford) https://doi.org/10.1093/rheumatology/kead186 (2023).

    Article  PubMed  Google Scholar 

  4. Preusse, C. et al. Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis. Acta Neuropathol. Commun. 4, 45 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bolko, L. et al. The role of interferons type I, II and III in myositis: a review. Brain Pathol. 31, e12955 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ladislau, L. et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain 141, 1609–1621 (2018).

    Article  PubMed  Google Scholar 

  7. Gallay, L. et al. Involvement of type I interferon signaling in muscle stem cell proliferation during dermatomyositis. Neurology 98, e2108–e2119 (2022).

    Article  CAS  PubMed  Google Scholar 

  8. Wang, J. et al. Engineered skeletal muscles for disease modeling and drug discovery. Biomaterials 221, 119416 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bersini, S. et al. Engineering an environment for the study of fibrosis: a 3d human muscle model with endothelium specificity and endomysium. Cell Rep. 25, 3858–3868 (2018).

    Article  CAS  PubMed  Google Scholar 

  10. Kinder, T. B., Dranchak, P. K. & Inglese, J. High-throughput screening to identify inhibitors of the type i interferon-major histocompatibility complex class i pathway in skeletal muscle. ACS Chem. Biol. 15, 1974–1986 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (project AR041215-02). The author thanks R. A. Colbert, I. Pinal-Fernandez, L. G. Rider and A. Schiffenbauer for their critical reading and input.

Author information

Authors and Affiliations

  1. Juvenile Myositis Pathogenesis and Therapeutics Unit, National Institute of Arthritis and Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, USA

    Hanna Kim

Authors
  1. Hanna Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hanna Kim.

Ethics declarations

Competing interests

H.K. is part of a clinical study at NIAMS that received grant support for under a government CRADA from Eli Lilly.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, H. Insights into juvenile myositis via engineered muscle. Nat Rev Rheumatol 19, 543–544 (2023). https://doi.org/10.1038/s41584-023-01003-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-023-01003-6

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing